Home

An INKmune Update, Catalysts Included…

~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company management. Thank...

ParkerVision’s Time is Nigh…

Knock me over with a feather but there's finally been some movement in the ParkerVision (PRKR) vs. Qualcomm (QCOM) trial in Orlando. This is...

Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute – Accelerating Path...

TW's Take: LP-184 has blockbuster potential. Excited to see it enter human trials later this year.  DALLAS, Jan. 12, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a...

Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™...

TW's Take: DERM continues to build out a strong core business. It is going to come down to execution and how well the sales...

Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral...

TW's Take: we believe that Mycapssa's unique oral delivery versus the competition will drive substantial sales for the product. Amryt is a compelling risk/reward...

Welcome to 2022?

So much for thinking 2022 was going to be an improvement over last year. Last Sunday I tested positive for covid then, on Monday,...

Movano Completes Blood Pressure Study with 110 Participants

TW's Take: Movano continues to progress towards development of an industry-leading health monitoring device. The glucose study in Q2 is very exciting as that...

Happy New Year!!!

Investing in micro-cap stocks with a 3-5 year time horizon, which is my expectation for a holding period every time I enter a position,...

Movano Unveils Smart Ring Designed for Women Seeking More Approachable Health Insights

TW's Take: Movano looks ready to exit stealth mode. We are big believers in the future of wearable medical technology and feel that Movano...

Trading Blog, December 22, 2021

~ Trade alerts discuss changes to Tailwinds' managed portfolios. They are available for premium subscribers only. The information contained here is not meant to...

TFF Pharmaceuticals Announces Final Data from Phase 1b Study of Inhaled Voriconazole Powder in...

TW's Take: we continue to believe, and the data supports this, that TFF's internal programs are worth more than the current market cap of...

Who Believes? Santa Rally Coming…

Yesterday it was 70 degrees in Charlottesville. While playing platform tennis in a t-shirt and shorts, the comment was made that it seems unlikely...

Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at...

TW's Take: more positive pre-clinical data supports the thesis that LP-284 may be effective in several types of rare cancers. DALLAS, Dec. 14, 2021 /PRNewswire/...

No QUESTion, This Stock’s A Winner

The irony of it all. While many companies scour the planet searching for potential gold mines, there's a garbage dump in the UK containing...

INmune Bio, Inc. Announces Key Breast Cancer Treatment Resistance Data to be Presented at...

TW's Take: the anti-inflammatory INB03 (also called XPro1595 in CNS indications) has broad-scale potential as TNF appears to be the master-cytokine, sparking inflammation that...

Quest Resource Holding Acquires Two Asset-Light Waste Services Companies

TW's Take: excellent news as QRHC adds to their revenue and EBITDA substantially without issuing more shares, making this highly accretive. Quest is entering...

Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective...

TW's Take: this program continues to make solid, albeit early-stage, progress. Covid isn't going away and Anixa has an opportunity here long-term. SAN JOSE, Calif....

Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce the Initiation of Rolling Submission of...

TW's Take: this drug, which has demonstrated great efficacy in a rare disease with no treatments, is likely to receive approval. With a PRV...

TFF Pharmaceuticals Hosting Science Day on December 13, 2021

TW's Take: the performance of Thin Film Freezing continues to excel in all aspects. This science day should help explain the multiple competitive advantages...

Bottom Picking

My constant refrain for most of 2021 has been that I don't like the market but love the stocks in my portfolio. I can...

Become a TW Research Member

All our articles are free for everyone to enjoy, however you must register as a user. Please take the time to sign up, it’s free and we do not share your information with anyone.

For those interested in receiving alerts when we buy or sell stocks for our managed accounts, you should consider becoming a premium subscriber. A premium subscription costs $500 per year and subscribers get emails about every transaction taken in our portfolios, including names that have yet to be added to the Tailwinds site.

SIGN ME UP

Receive Our Weekly Newsletter

Every Sunday we recap the market and consolidate the news from our universe. It’s free to subscribe. Just click on the link below.

Newsletter Signup

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.